AG490对实验性自身免疫性重症肌无力大鼠的治疗作用
Therapeutic effects of AG490 on experimental autoimmune myasthenia gravis in Lewis rats

DOI: 10.6040/j.issn.1671-7554.0.2015.796

Keywords: 实验性自身免疫性重症肌无力,AG490,IL-6,IL-21,抗R97-116抗体,
Anti-R97-116 antibody,AG490,IL-21,Experimental autoimmune myasthenia gravis,IL-6

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway[J]. J Immunol, 2001, 166(5):3491-3498.
[2]	Davoodi-Semiromi A, Hassanzadeh A, Wasserfall CH, et al. Tyrphostin AG490 agent modestly but significantly prevents onset of type 1 in NOD mouse; implication of immunologic and metabolic effects of a Jak-Stat pathway inhibitor[J]. J Clin Immunol, 2012, 32(5):1038-1047.
[3]	Dienz O, Eaton SM, Bond JP, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4<sup>+</sup> T cells[J]. J Exp Med, 2009, 206(1):69-78.
[4]	Kusner LL, Kaminski HJ. The role of complement in experimental autoimmune myasthenia gravis[J]. Ann N Y Acad Sci, 2012, 1274(1):127-132.
[5]	Aricha R, Mizrachi K, Fuchs S, et al. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis[J]. J Autoimmun, 2011, 36(2):135-141.
[6]	刘莹,李晓丽,徐华,等. 小剂量阿托伐他汀对实验性自身免疫性重症肌无力大鼠的治疗作用[J]. 山东大学学报(医学版),2012, 50(7):26-31. LIU Ying, LI Xiaoli, XU Hua, et al. Effects of lower dose of atorvastatin on experimental autoimmune myasthenia gravis in rats[J]. Journal of Shandong University(Health Sciences), 2012, 50(7):26-31.
[7]	Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic TH 17 cells in the absence of TGF-β 2 signalling[J]. Nature, 2010, 467(7318):967-971.
[8]	Lee SK, Rigby RJ, Zotos D, et al. B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells[J]. J Exp Med, 2011, 208(7):1377-1388.
[9]	Tuzun E, Allman W, Ulusoy C, et al. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis[J]. Ann N Y Acad Sci, 2012, 1274:133-139. doi:10.1111/j.1749-6632.2012.06773.x.
[10]	Huda R, Strait RT, Tuzun E, et al. IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice[J]. J Neuroimmunol, 2015, 281:68-72. doi:10.1016/j.jneuroim.2015.03.004.
[11]	Kuchen S, Robbins R, Sims GP, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4<sup>+</sup> T cell-B cell collaboration [J]. J Immunol, 2007, 179(9):5886-5896.
[12]	Diehl SA, Schmidlin H, Nagasawa M, et al. STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation[J]. J Immunol, 2008,180(7):4805-4815.
[13]	Ha JC, Richman DP. Myasthenia gravis and related disorders:pathology and molecular pathogenesis[J]. Biochem Biophys Acta, 2015, 1852(4):651-657.
[14]	Souroujon MC, Brenner T, Fuchs S. Development of novel therapies for MG:studies in animal models [J]. Autoimmunity, 2010, 43(5-6):446-460.
[15]	Diehl SA, Schmidlin H, Nagasawa M, et al. IL-6 triggers IL-21 production by human CD4<sup>+</sup> T cells to drive STAT3-dependent plasma cell differentiation in B cells[J]. Immunol Cell Biol, 2012, 90(8):802-811.
[16]	Baggi F, Annoni A, Ubiali F, et al. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats[J]. J Immunol, 2004, 172(4):2697-2703.
[17]	Park JS, Lee J, Lim MA, et al. JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells[J]. J Immunol, 2014, 192(9):4417-4424.
[18]	王志强,张志坚,吴立坚,等. 重症肌无力患者外周血单个核细胞TNF-α和IL-6水平在疾病转归中的动态变化[J]. 中国神经免疫学和神经病学杂志, 2009, 16(2):90-93. WANG Zhiqiang, ZHANG Zhijian, WU Lijian, et al. The dynamic changes of tumor necrosis factor-α and interleukin-6 in peripheral blood mononuclear cells in patients with myasthenia gravis[J]. Clin J Neuroimmunol & Neurol, 2009, 16(2):90-93.
[19]	Seo IA, Lee HK, Shin YK, et al. Janus kinase 2 inhibitor AG490 inhibits the STAT3 signaling pathway by suppressing protein translation of gp130[J]. Korean J Physiol Pharmacol, 2009, 13(2):131-138.
[20]	Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans[J]. J Exp Med, 2010,207(1):155-171.
[21]	Niu X, He D, Zhang X, et al. IL-21 regulates Th17 cells in rheumatoid arthritis[J]. Hum Immunol, 2010, 71(4):334-341.
[22]	Costanzo A, Chimenti MS, Botti E, et al. IL-21 in the pathogenesis and treatment of skin diseases[J]. J Dermatol Sci, 2010, 60(2):61-66.
[23]	Zhang M, Zhou Y, Guo J, et al. Thymic TFH cells involved in the pathogenesis of myasthenia gravis with thymoma[J]. Exp Neurol, 2014, 254:200-205. doi:10.1016/j.expneurol.2014.01.024.
[24]	Davis ID, Skak K, Smyth MJ, et al. Interleukin-21 signaling:functions in cancer and autoimmunity [J]. Clin Cancer Res, 2007, 13(23):6926-6932.
[25]	Huda R, Tuzun E, Christadoss P. Complement C2 siRNA mediated therapy of myasthenia gravis in mice[J]. J Autoimmun, 2013, 42:94-104. doi:10.1016/j.jaut.2013.01.003.

Full-Text